Journal of Intensive Care Medicine

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Chowdhry, R.
Right arrow Articles by Marshall, W. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chowdhry, R.
Right arrow Articles by Marshall, W. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Intensive Care Medicine, Vol. 23, No. 3, 151-158 (2008)
DOI: 10.1177/0885066607313000

Reviews

Analytical Reviews: Antifungal Therapies in the Intensive Care Unit

Ranjan Chowdhry, MD

Division of Infectious Disease, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts

William L. Marshall, MD

Division of Infectious Disease, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, william.marshall{at}umassmed.edu

Fungal infections are increasing nationwide, paralleling increases in the number of immunosuppressed hosts. Most of the candida infections seen in the intensive care unit are likely due to iatrogenic factors such as hyperalimentation, catheters, broad-spectrum antibiotics, and postprocedure complications that are prevalent in intensive care unit patients. Delays in appropriate therapy are common and may compromise care. Fortunately, the recognition of several clinical syndromes in the intensive care unit that require specialized treatment can improve outcomes. The issue of antifungal prophylaxis has to be balanced against issues of resistance, and current guidelines are reviewed here for prophylactic use of fluconazole only in selected intensive care unit patients. Finally, several new antifungal agents are available to treat the emerging resistant fungi, with better toxic/therapeutic ratios than in the past. Thus, there are an increasing number of safer and more effective options for treating fungal infections in the intensive care unit.

Key Words: posaconazole • itraconazole • ICU • catheter • fungemia • candida • aspergillus • fluconazole • amphotericin B • echinocandin • caspofungin • anidulafungin • voriconazole • micafungin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?